Administrators, Editors, Administrators
3,484
edits
Changes
Jump to navigation
Jump to search
+How soon
;Choice of modality
Ultrasonography is the first-line modality of medical imaging in patients with suspected cirrhosis and/or portal hypertension.<ref name="ProcopetBerzigotti2017">{{cite journal|last1=Procopet|first1=Bogdan|last2=Berzigotti|first2=Annalisa|title=Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy|journal=Gastroenterology Report|volume=5|issue=2|year=2017|pages=79–89|issn=2052-0034|doi=10.1093/gastro/gox012}}</ref> US is also typically the initial, first-line modality choice for the diagnosis and follow-up of portal hypertension.<ref name="BandaliMirakhur2017">{{cite journal|last1=Bandali|first1=Murad Feroz|last2=Mirakhur|first2=Anirudh|last3=Lee|first3=Edward Wolfgang|last4=Ferris|first4=Mollie Clarke|last5=Sadler|first5=David James|last6=Gray|first6=Robin Ritchie|last7=Wong|first7=Jason Kam|title=Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy|journal=World Journal of Gastroenterology|volume=23|issue=10|year=2017|pages=1735|issn=1007-9327|doi=10.3748/wjg.v23.i10.1735}}</ref> For cirrhosis, it should be done without IV contrast.
===How soon===
In Swedish practice, ultrasonography for suspected cirrhosis should be done within 2 months.<ref group=notes">{{NU Hospital Group}}</ref>
In patients with known cirrhosis, surveillance [[ultrasonography of hepatocellular cancer]] (HCC) is indicated, generally every 6 months.<ref name="FateenRyder2017">{{cite journal|last1=Fateen|first1=Waleed|last2=Ryder|first2=Stephen|title=Screening for hepatocellular carcinoma: patient selection and perspectives|journal=Journal of Hepatocellular Carcinoma|volume=Volume 4|year=2017|pages=71–79|issn=2253-5969|doi=10.2147/JHC.S105777}}</ref>
==Diagnosis==
